LexaGene Receives Purchase Order for MiQLab from Ethos Discovery
December 15 2020 - 7:58AM
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the
“
Company”), a molecular diagnostics company that
develops fully automated rapid pathogen detection systems, is
pleased to announce it has received a purchase order for a MiQLab™
system from Ethos Discovery.
Dr. Chand Khanna, DVM, PhD, DACVIM (Onc), DACVP (Hon), the
President of Ethos Discovery, comments, “We are very excited to
purchase a MiQLab system and look forward to using the validated
test panel to quickly diagnose infections. In veterinary health,
there are many unmet clinical diagnostic needs where LexaGene’s
technology can be of great value.” He continues, “In 2021, we will
collaborate with LexaGene on expanding the MiQLab’s capabilities to
pursue additional diagnostic innovation in areas that are important
for Ethos. We are thrilled to have the first point-of-care
molecular diagnostic instrument available to veterinary health
professionals and look forward to bringing this technology to Ethos
hospitals in the future.”
LexaGene’s MiQLab is designed for use inside veterinary
hospitals, where it will be run by veterinarians and clinic staff.
The automated system is easy to use and is currently equipped with
LexaGene’s Bacterial and AMR Panel capable of screening samples for
the 7 most common bacterial pathogens and 13 anti-microbial
resistance markers. Rapid, in-hospital identification of pathogens
and whether they are resistant to common therapies, is extremely
useful for veterinarians in making evidence-based patient care
decisions. LexaGene’s MiQLab tests samples using real-time PCR,
which is widely regarded as a gold-standard chemistry for its
sensitivity and specificity.
Dr. Jack Regan, LexaGene’s CEO and Founder, states, “Up until
now, veterinarians have had limited options for infectious disease
testing. Generally, veterinarians send collected samples to
reference laboratories and wait up to 5 days or more to receive the
results. This slow turn-around time and delay in proper treatment
can be frustrating to many veterinarians and potentially harmful to
their patients. With the MiQLab, we are changing veterinary
diagnostics. Veterinarians will now have the opportunity to adopt
an automated, rapid, in-hospital, reference laboratory quality
testing solution so they can deliver world-class care. We are
gaining traction by steadily building momentum with MiQLab in the
veterinary market and are looking forward to meeting the demand and
fulfilling orders in 2021.”
To be added to the LexaGene email list, please subscribe on the
Company website.
On Behalf of the Board of DirectorsDr.
Jack ReganChief Executive Officer &
Director
About LexaGene Holdings Inc.LexaGene is a
molecular diagnostics company that develops molecular diagnostic
systems for pathogen detection and genetic testing for other
molecular markers for on-site rapid testing in veterinary
diagnostics, food safety and for use in open-access markets such as
clinical research, agricultural testing and biodefense. End-users
simply need to collect a sample, load it onto the instrument with a
sample preparation cartridge, enter sample ID and press ‘go’. The
MiQLab™ system delivers excellent sensitivity, specificity, and
breadth of detection and can return results in approximately one
hour. The unique open-access feature is designed for custom testing
so that end-users can load their own real-time PCR assays onto the
instrument to target any genetic target of interest.
About Ethos DiscoveryEthos Discovery is a
501(c)3 nonprofit organization devoted to delivering innovations
that will improve the outcome for pets and humans afflicted with
complex medical problems. Ethos Veterinary Health,
LLC formed Ethos Discovery to conduct nonprofit scientific
research to advance veterinary and human medical science in
December 2016. For more information,
visit https://www.ethosdiscovery.org
About Ethos Veterinary HealthEthos is a
veterinary health company with hospitals across the U.S. providing
advanced medical care for pets. Our approach includes a focus on
transformative science, continuous learning and growth for team
members and collaboration. For more information, visit
https://www.ethosvet.com
For further information, please contact:
Media ContactsNicole RidgedaleDirector of
Corporate Marketing, LexaGene800.215.1824 ext
206nridgedale@lexagene.com
Investor RelationsJay AdelaarVice President of
Capital Markets, LexaGene800.215.1824 ext
207jadelaar@lexagene.com
The TSX Venture Exchange Inc. has in no way
passed upon the merits of the proposed transaction and has neither
approved nor disapproved the contents of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This news release contains forward-looking information, which
involves known and unknown risks, uncertainties and other factors
that may cause actual events to differ materially from current
expectation. Important factors -- including the availability of
funds, the results of financing efforts, the success of technology
development efforts, the cost to procure critical parts,
performance of the instrument, market acceptance of the technology,
regulatory acceptance, and licensing issues -- that could cause
actual results to differ materially from the Company's expectations
as disclosed in the Company's documents filed from time to time on
SEDAR (see www.sedar.com). Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The company disclaims
any intention or obligation, except to the extent required by law,
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jul 2023 to Jul 2024